Word: fda
(lookup in dictionary)
(lookup stats)
Dates: during 2000-2009
Sort By: most recent first
(reverse)
...exclusive interview with TIME, Silverman provided a list of 34 studies the company included in its FDA application, including one of the three mentioned in the AP article, which showed that less than 1% of 4,279 chipped mice developed tumors "clearly due to the implanted microchips" but were otherwise healthy, and that "no clinical symptoms except the nodule on their backs were shown." The second study, conducted in France in 2006, two years after VeriChip's FDA application was approved, found that while 4% of the 1,260 mice in the study developed tumors, none of them were malignant...
...found a link between the chips and cancer, says McGill. If there were a problem, he says, we would have already seen lots of cancer among the approximately 10 million pets that have been chipped over the past 15 years. Says Silverman, "There are no reported incidents to the FDA of any cancer formation around that...
...Bionovo, the drug discovery and development company in Emeryville, Calif., that's behind BZL101, there's hope too. The trial is the first FDA-validated clinical study of a potential cancer drug derived from a Chinese medicinal herb, says Dr. Mary Tagliaferri, a co-founder of the company, former practicing acupuncturist and a breast-cancer survivor. "Sixty-two percent of chemotherapy drugs come from natural products, and plants have been the basis of almost every new class of medication," she says. "It makes sense that these plants can act as anticancer agents...
...university's Carol Franc Buck Breast Care Center. Over the next several years, the trio amassed enough evidence about the herb's anticancer properties - in lab tests of animals and breast-cancer cells, BZL101 caused apoptosis or cell death, according to Tagliaferri - to get a green light from the FDA to begin clinical trials...
...FDA at least is eager to see more studies of botanical treatments of cancer. "We're not opposed to Chinese medicine," says Dr. Shaw Chen, botanical review team leader at the FDA. "We just like to see clinical studies that meet our standards." Chen agrees it can be tough to study the pharmacological activity of botanical compounds or to ensure consistency in quality, but Bionovo's efforts, if fruitful, may help pave the way for other research. "A successful application to market for a cancer drug based on Chinese medicine will be encouragement to the industry," he says. "I think...